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Abstract
Pneumocystis jirovecii is a poorly understood pathogen that causes opportunistic pneumonia (Pneumocystis pneumonia (PcP)) in patients
with AIDS. The present study was aimed at correlating genetic differences in P. jirovecii isolates and clinical patient data. A description of
genetic diversity in P. jirovecii isolates from human immunodeﬁciency virus-positive patients, based on the identiﬁcation of multiple sin-
gle-nucleotide polymorphisms (SNPs) at ﬁve distinct loci encoding mitochondrial large-subunit rRNA (mtLSU rRNA), cytochrome b
(CYB), superoxide dismutase (SOD), dihydrofolate reductase (DHFR), and dihydropteroate synthase (DHPS), was achieved using PCR
with DNA sequencing and restriction fragment length polymorphism analysis. The statistical analysis revealed several interesting correla-
tions among the four most relevant SNPs (mt85, SOD110, SOD215, and DHFR312) and speciﬁc clinical parameters: mt85C was associ-
ated with undiagnosed or atypical PcP episodes and favourable follow-up; SOD215C was associated with favourable follow-up; and
DHFR312T was associated with PcP cases presenting moderate to high parasite burdens. The genotypes mt85C/SOD215C and SOD110T/
SOD215C were found to be associated with less virulent P. jirovecii infections, whereas the genotype SOD110T/SOD215T was found to
be related to more virulent PcP episodes. The present work demonstrated that potential P. jirovecii haplotypes may be related to the
clinical data and outcome of PcP.
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Introduction
Pneumocystis jirovecii [1] causes serious clinical problems
among human immunodeﬁciency virus (HIV)-infected
patients, usually in the form of a severe life-threatening pneu-
monia (Pneumocystis pneumonia (PcP)) [2–4]. Although sev-
eral prognostic indicators have been associated with the
outcome of PcP [3–6], advances in understanding the genetic
diversity of P. jirovecii have shown that speciﬁc polymor-
phisms could determine epidemiological proﬁles of the path-
ogen, including geographical distribution, drug resistance,
virulence, and modes of transmission [7–12]. The conse-
quences of a single-nucleotide polymorphism (SNP) for cellu-
lar activity depend on where in the genome the SNP occurs.
It is established that SNPs located in the coding regions may
have impacts at the phenotypic level, altering gene function
or the structure of the encoded proteins. SNPs positioned in
non-coding regions may affect gene function by altering the
DNA splicing and stability or even protein quantity and avail-
ability [13,14].
The aims of this study were to: (i) identify relevant SNPs
encoded at ﬁve P. jirovecii loci—the mitochondrial small-
subunit rRNA (mtLSU rRNA), cytochrome b (CYB), super-
oxide dismutase (SOD), dihydrofolate reductase (DHFR) and
dihydropteroate synthase (DHPS) genes; and (ii) investigate
possible associations between nucleotide sequences and
parasite burden, demographic patient data, and clinical
parameters.
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Materials and Methods
Subjects and data
In total, 102 pulmonary specimens (38 induced sputa and
64 bronchoalveolar lavage ﬂuids) tested previously and
found to be positive for P. jirovecii were obtained from 96
HIV-positive adult Portuguese patients (1997–2007). Two
specimens were collected during the same PcP episode
from six of the 96 patients. The mean patient age was
30 years (range: 24–69 years), and most were men (68%).
Detection of P. jirovecii organisms was performed by ampliﬁ-
cation of the mtLSU rRNA gene using nested-PCR as previ-
ously described [15]. The parasite burden was quantiﬁed by
scoring the number of cysts observed, using indirect immu-
noﬂuorescence with monoclonal antibodies (IF) [MonoFluo
kit P. jirovecii (Bio-Rad)] as follows: low (no cysts identiﬁed,
but positive by PCR); moderate (one to three cysts in 30
ﬁelds at ·1000 magniﬁcation); and high (four to 30 or
more cysts in one ﬁeld at ·1000 magniﬁcation). A clinical
diagnosis of PcP was considered when at least two of the
following variables were present: symptoms such as unpro-
ductive cough, fever, and dyspnoea; suggestive chest radio-
graphs (ﬁne bilateral, perihilar interstitial shadowing); and
arterial partial pressure of oxygen (PaO2) lower than
65 mmHg. Positive follow-up was considered when the
patient showed a favourable response to anti-P. jirovecii
therapy and survived for at least 4 weeks after the diagno-
sis of PcP. Follow-up was negative either when there was a
negative response to anti-P. jirovecii therapy (failure to
improve clinically after administration of the drug for more
than 10 days) or when the patient died during a PcP
episode. Data on parasite burden, clinical diagnosis of PcP,
follow-up, CD4+ T-lymphocyte counts and anti-P. jirovecii
prophylaxis and therapy are summarized in Table 1.
SNP analysis
SNPs were selected targeting speciﬁc genomic regions
reported previously to be important polymorphic spots and
respecting the selection criteria: location, type of change
promoted, and frequency and spacing throughout the region
of interest [16–21]. The mtLSU rRNA and DHFR genes were
ampliﬁed by applying two pairs of primers described previ-
ously (pAZ102-X and pAZ102-E, and FR 208 and FR 1018)
[15,18,22]. The oligonucleotide sequences for CYB and SOD
gene ampliﬁcation (CytbFw, 5¢-CCCAGAATTCTCGTTTGG
TCTATT-3¢; CytbRw, 5¢-AAGAGGTCTAAAAGCAGAACC
TCAA-3¢; and MnSODFw, 5¢-GGGTTTAATTAGTCTTT
TTAGGCAC-3¢; and MnSODRw, 5¢-CATGTTCCCACGC
ATCCTAT-3¢) were designed using the on-line bioinformat-
ics software Primer 3.0 (http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3.cgi). DNA fragments were ampliﬁed by sin-
gle-round PCR with an annealing temperature of 61.5C.
PCR products were puriﬁed and directly sequenced on both
strands (dominating fractions, which constitute more than
20% of the DNA in a sample, were detected and sequenced)
[11,21,23]. Characterization of the DHPS gene was per-
formed using nested-PCR followed by restriction fragment
length polymorphism analysis, as described elsewhere
[17,21].
Data analysis
Chi-square tests were applied to investigate the association
between qualitative variables at a signiﬁcance level of p 0.05
using SPSS v.16.0 software (SPSS Inc., Chicago, IL, USA). A
principal components analysis (PCA) was performed in order
to establish correlations between SNPs and patient data
using the Numerical Taxonomy System—NTSYSpc, v. 2.2.
This standard non-parametric method involves a linear trans-
formation of variables into a coordinate system in which the
greatest variance by any projection of the data corresponds
to the ﬁrst coordinate (ﬁrst principal component) and all
succeeding greatest variances correspond to the remaining
components [24].
Results
Of 102 pulmonary specimens analysed in the present study,
78 (76%) were collected from patients with proven PcP
TABLE 1. Clinical information and parameters of disease of
the patients involved in the study
Clinical characteristic
Number (%)
of subjects
Parasite burden 102
Low 25 (24)
Moderate 54 (53)
High 23 (23)
Diagnosis 102
Clinical diagnosis of PcP 77 (75)
Clinical course difﬁcult to interpret 25 (25)
CD4+ T-lymphocytes count 81
>200 cells/lL 8 (10)
50–200 cells/lL 21 (26)
<50 cells/lL 52 (64)
Follow-up 46
Positive follow-up 32 (70)
Negative follow-up 14 (30)
Prophylaxis 88
Non-anti-Pneumocystis jirovecii prophylactic regimen 64 (73)
Trimethoprim–sulphamethoxazole at prophylactic dose 24 (27)
Therapy 84
Non-anti-P. jirovecii therapeutic regimen 20 (24)
Trimethoprim–sulphamethoxazole at therapeutic dose 64 (76)
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(positive PCR, positive IF, fulﬁlling clinical diagnostic criteria
for PcP), 16 (16%) were obtained from patients with undiag-
nosed PcP or atypical PcP presentation (positive PCR, posi-
tive IF, not fulﬁlling clinical diagnostic criteria for PcP), and
eight (8%) were collected from patients with P. jirovecii colo-
nization or subclinical infection (positive PCR, negative IF,
not fulﬁlling clinical diagnostic criteria for PcP). Overall, 94
(92%) isolates were obtained from patients with P. jirovecii
infection conﬁrmed by positive IF.
SNP analysis
On consideration of the large amount of sequence data
derived from the analysis of the target regions, a set of SNPs
were recognized as the most common among the sequenced
isolates. Genotyping results and SNP frequencies are summa-
rized in Table 2. From the 102 pulmonary specimens, DNA
was successfully ampliﬁed and sequenced in 92 (90%) cases
for the mtLSU rRNA gene, in 70 (69%) for the DHFR gene,
and in 83 (81%) for the DHPS gene. Owing to there being
only small amounts of DNA from 22 of the 102 isolates, it
was not possible to analyse the CYB and SOD loci in all
pulmonary specimens included in the study. Instead, these
two genes were investigated in the 80 (78%) remaining iso-
lates. The CYB and SOD loci were successfully characterized
in 49 (61%) and 46 (58%) isolates, respectively.
Of the six patients with two specimens collected during
the same PcP episode, three showed SNP changes between
the ﬁrst and the second collection. In one patient, mt248T in
the ﬁrst specimen changed to mt248C in the second speci-
men. In another patient, mt85T in the ﬁrst specimen was
altered to mt85C in the second specimen. Finally, in the third
patient, the SNP combination mt85C/SOD110T/SOD215C in
the ﬁrst specimen changed to mt85A/SOD110C/SOD215T in
the second specimen. In these three cases, the remaining
polymorphic bases were identical in both specimens col-
lected during the episodes.
Data analysis
The descriptive statistical analysis for qualitative data was
performed by crossing the SNP genotyping results with the
parasite burden, demographic patient information, and clinical
parameters. The isolates containing more than one nucleo-
tide at a single base contributed with two or more punative
genotypes for the associated variations and cross-genetic
statistical tests.
Uniform distribution of the SNPs was observed during the
experimental period, and no association was found between
polymorphisms and the year or season in which the episodes
of P. jirovecii infection occurred. No statistically signiﬁcant
associations were found between SNPs and patient age, gen-
der, CD4+ T-lymphocyte count, and anti-P. jirovecii prophy-
laxis or therapy.
The distribution frequencies of the most relevant clinical
parameters (parasite burden and follow-up) among the lar-
gely representative SNPs and genotypes, detected in patients
with P. jirovecii infection conﬁrmed by positive IF, are
depicted in Table 3. The data showed that a low parasite
burden was more common among isolates presenting mt85C
(20%), SOD215C (21%), and DHFR312C (33%), whereas a
high parasite burden was more frequently detected in iso-
lates with mt85A (29%), mt85T (32%), SOD110C (32%),
SOD215T (31%), and DHFR312T (28%). Isolates with mt85C
and SOD215C corresponded more frequently to patients
with positive follow-up (95% (p 0.002) and 100% (p 0.004),
respectively), whereas isolates with mt85A (32%), mt85T
(40%), SOD110C (32%) and SOD215T (36%) were more com-
mon in patients with negative follow-up. The cross-genetic
analysis demonstrated several statistically signiﬁcant associa-
tions: SOD215C was more common among isolates with
mt85C (65%; p 0.010); DHFR312T was more frequent among
isolates with mt85A (95%; p 0.045); SOD215T was more fre-
quent among isolates with SOD110C (93%; p 0.001); and
SOD215C was more common among isolates with SOD110T
(68%; p 0.004). Among 41 isolates successfully sequenced for
mt85 and SOD215, the genotype mt85C/SOD215C was
TABLE 2. Pneumocystis jirovecii single-nucleotide polymor-
phisms (SNPs) detected at the ﬁve studied loci
Locus SNP
Nucleotide
(amino acid)
position: identity
Number (%)
of isolates
mtLSU rRNA mt85C 85: C 46 (50)
mt85A 85: A 19 (21)
mt85T 85: T 14 (15)
mt85C/Ta 85: C/T 9 (10)
mt85C/Aa 85: C/A 3 (3)
mt85A/Ta 85: A/T 1 (1)
mt248C 248: C 83 (90)
mt248T 248: T 7 (8)
mt248C/Ta 248: C/T 2 (2)
CYB CYB838C 838 (280): C (Leu) 39 (80)
CYB838T 838 (280): T (Phe) 8 (16)
CYB838C/Ta 838 (280): C/T (Leu/Phe) 2 (4)
SOD SOD110C 110: C 27 (59)
SOD110T 110: T 17 (37)
SOD110C/Ta 110: C/T 2 (4)
SOD215T 215 (41): T (Asp) 26 (57)
SOD215C 215 (41): C (Asp) 13 (28)
SOD215C/Ta 215 (41): C/T (Asp) 7 (15)
DHFR DHFR312T 312 (117): T (Gly) 55 (79)
DHFR312C 312 (117): C (Gly) 14 (20)
DHFR312C/Ta 312 (117): C/T (Gly) 1 (1)
DHPS DHPS165A 165 (55): A (Thr) 77 (93)
DHPS165G 165 (55): G (Ala) 3 (4)
DHPS165A/Ga 165 (55): A/G (Thr/Ala) 3 (4)
DHPS171C 171 (57): C (Pro) 76 (92)
DHPS171T 171 (57): T (Ser) 4 (5)
DHPS171C/Ta 171 (57): C/T (Pro/Ser) 3 (4)
aIsolates containing more than one nucleotide at a single base.
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detected in 11 (27%). Among those, all were collected from
patients with positive follow-up (100%; p 0.029). Among the
44 isolates successfully sequenced for SOD110 and SOD215,
the genotype SOD110T/SOD215C was detected in ten (23%).
Positive follow-up was also observed in all patients with the
genotype SOD110T/SOD215C (100%; p 0.028) (Table 3).
To further explore the results obtained, a PCA was also
performed, conﬁrming several associations between SNPs and
clinical data. The three most informative graphs of the PCA
are shown in Fig. 1. Fig. 1a shows that a moderate to high par-
asite burden was more frequent in patients with isolates with
DHFR312T (D2). Fig. 1b shows that mt85C (D2) was more
common among isolates from patients with positive IF but not
fulﬁlling clinical diagnostic criteria for PcP. Fig. 1c shows that
proven PcP cases were more common in patients with iso-
lates with SOD110C/SOD215T (D1). The three graphs reveal
that SOD110C was persistently associated with SOD215T, just
as SOD110T was associated with SOD215C (D1).
Discussion
P. jirovecii multilocus genotyping allows simultaneous charac-
terization of SNPs at several genetic loci, thereby providing
more robust information than genotyping at a single locus. In
the present study, eight speciﬁc P. jirovecii SNPs in ﬁve inde-
pendent loci were studied in specimens collected from HIV-
positive patients. The association between polymorphisms
and the intensity of infection, clinical data and demographic
patient data was investigated. Four SNPs, at mt85, SOD110,
SOD215, and DHFR312, proved to be associated with several
clinical parameters.
The SNP at position 85 of the mtLSU rRNA gene was
detected frequently. The presence of a cytosine at this
position was associated with undiagnosed or atypical PcP epi-
sodes (PcP cases conﬁrmed by positive IF, but not fulﬁlling
the clinical diagnostic criteria) and positive follow-up. SNP
mt85C may be related to less virulent PcP cases. Nucleotide
variation may inﬂuence secondary structures of rRNA,
thereby having an impact on ribosomal conformation and
activity [25]. The SNP at base 248 proved to be much less
frequent, and neither mt248C nor mt248T was associated
with patient data.
Studies of the P. jirovecii cytochrome b showed that it con-
tains mutations in the Q0 region, one of two ubiquinone-
binding sites, in patients receiving atovaquone (a ubiquinone
analogue that inhibits electron transport at the cyto-
chrome bc1 complex) prophylaxis against PcP [19,26]. During
the present study, the SNP at position 838 of the CYB locus
was recognized as relevant. However, this point mutation at
amino acid position 280 does not concern the Q0 region,
and no statistically signiﬁcant associations were observed
between the SNP and the clinical parameters. None of the
subjects enrolled in the present study had been treated with
atovaquone.
SODs are ubiquitous enzymes protective against free oxy-
gen radicals [27]. Genetic diversity at bases 110 and 215 of
the P. jirovecii SOD locus was reported previously by other
authors [20,27–29] Data from the present study show that
SOD215C was statistically associated with positive follow-up.
The synonymous SNP at position 215 does not alter amino
acid coding, and therefore it is not expected to change the
function of the protein.
Nevertheless, it is established that synonymous polymor-
phisms could cause interference with protein activity as a
result of association with a haplotype involving other func-
tional non-synonymous polymorphisms, or as a consequence
of allele-speciﬁc differences in mRNA folding that could inﬂu-
ence the splicing process, or translational control and regula-
tion [30,31].
TABLE 3. Distribution frequencies
(%) of parasite burden and follow-
up with respect to the most rele-
vant single-nucleotide polymor-
phisms (SNPs) and genotypes
detected in the study
SNPs and
genotypes
Parasite burden (n (%)) Follow-up (n (%))
Low Moderate High Positive lNegative
mt85C 10 (20) 31 (60) 10 (20) 20 (95)a 1 (5)
mt85A 2 (8) 15 (63) 7 (29) 13 (68) 6 (32)
mt85T 3 (14) 12 (54) 7 (32) 6 (60) 4 (40)
SOD110C 3 (11) 16 (57) 9 (32) 13 (68) 6 (32)
SOD110T 3 (17) 11 (61) 4 (22) 12 (75) 4 (25)
SOD215T 3 (10) 19 (59) 10 (31) 16 (64) 9 (36)
SOD215C 4 (21) 10 (53) 5 (26) 14 (100)a 0 (0)
DHFR312T 10 (18) 29 (54) 15 (28) 26 (76) 8 (24)
DHFR312C 4 (33) 5 (42) 3 (25) 3 (75) 1 (25)
mt85C/SOD215C 4 (36) 5 (46) 2 (18) 11 (100)a 0 (0)
mt85A/DHFR312T 2 (11) 12 (63) 5 (26) 12 (75) 4 (25)
SOD110C/SOD215T 3 (11) 15 (58) 8 (31) 13 (68) 6 (32)
SOD110T/SOD215C 3 (27) 6 (55) 2 (18) 10 (100)a 0 (0)
aStatistically signiﬁcant associations (p <0.05).
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Trimethoprim–sulphamethoxazole was the key agent for
treatment and prophylaxis of PcP in the studied subjects.
Whereas trimethoprim inhibits DHFR, sulphamethoxazole
targets DHPS, both enzymes of the folic acid pathway. DHFR
converts dihydrofolate into tetrahydrofolate during the
biosynthetic pathway, providing thymidylic acid, several
amino acids and a methyl group for de novo synthesis of pu-
rines [32]. In this study, the presence of a thymine at nucleo-
tide position 312 of the DHFR locus was associated with PcP
cases presenting moderate to high parasite burdens.
Other studies have consistently demonstrated a signiﬁcant
association between the use of sulfa drugs for PcP prophy-
laxis and the SNPs at bases 165 and 171 of the DHPS locus
[8,33]. In the present study, these SNPs were detected at
low frequencies, conﬁrming the decline of DHPS mutations
in Portugal. These results were identical to those found in
other recent European studies, and may be related to the
decreased use of sulfa prophylaxis after the introduction of
highly active antiretroviral therapy [8,17,21,34]. There were
no statistically signiﬁcant associations between these muta-
tions and clinical parameters, especially with PcP prophylaxis
failure or negative follow-up.
The success rates for amplifying and sequencing CYB, SOD
and DHFR gene fragments were relatively low. This may be
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FIG. 1. Graphic representation of the three most informative principal component analyses. (a) Distribution of isolates with moderate to high
parasite burden among the Pneumocystis jirovecii single-nucleotide polymorphisms (SNPs). The ﬁrst principal dimension (D1), which explains 42%
of the total variance, was correlated with the SOD110 and SOD215. The second principal dimension (D2), which explains 25% of the total vari-
ance, was correlated with DHFR312. (b) Distribution of isolates collected from patients with undiagnosed PcP or atypical PcP presentation
among the P. jirovecii SNPs. The ﬁrst principal dimension (D1), which explains 51% of the total variance, was correlated with SOD110, SOD215,
and DHFR312. The second principal dimension (D2), which explains 19% of the total variance, was correlated with mt85. (c) Distribution of iso-
lates from proven PcP cases among the P. jirovecii SNPs. The ﬁrst principal dimension (D1), which explains 36% of the total variance, was corre-
lated with mt85, SOD110, and SOD215. The second principal dimension (D2), which explains 25% of the total variance, was correlated with
mt85 and DHFR312.
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the consequence of a low parasite burden and/or the fact
that there are experimental conditions inherent to the PCR
methodology that may inﬂuence the ampliﬁcation rates of
these speciﬁc loci. Additionally, the modest ampliﬁcation rate
observed for SOD and DHFR gene sequences may be due to
the fact that they occur in single copies in the P. jirovecii
genome [27,35]. SNPs at the mtLSU rRNA locus were
observed frequently, probably because it is located in mito-
chondrial DNA, where polymorphism rates are higher than
in the nucleus of the cell [19,36]. The presence of multiple
nucleotides at one SNP base position in the same isolate
may be explained by the presence of different mitochondrial
genomes in the same cell; alternatively, heterozygous organ-
isms, or even genetically different P. jirovecii variants, might
be infecting a single host. Detection of different genotypes in
three patients, during one PcP episode in each case, suggests
that different P. jirovecii clones could be present. This could
be simply due to mixed infections combined with inadequate
sampling or to the inability to reveal the presence of organ-
isms that constituted a minor fraction of the total organisms
in the sample [11,21,37]. The occurrence of SNP switching
detected by direct sequencing suggests that heterogeneous
populations of P. jirovecii organisms could be infecting a single
host and that genotype proportions can be altered during
one and the same PcP episode.
The cross-genetic analysis established several statistical
associations among the SNPs studied: mt85C/SOD215C,
mt85A/DHFR312T, SOD110C/SOD215T, and SOD110T/
SOD215C. The genotypes mt85C/SOD215C and SOD110T/
SOD215C were detected mainly in PcP cases with favourable
follow-up. Apparently, these genotypes were statistically sig-
niﬁcantly associated with less virulent PcP cases. The geno-
type SOD110T/SOD215T was more frequently observed
among proven PcP cases, suggesting that this genotype could
be related to more virulent P. jirovecii variants.
The present work showed that there are potential haplo-
type candidates to be studied in further investigations involving
more samples and clinical data. Therefore, genetic character-
ization could be used as an adjunct to clinical decision-making
in the management of PcP. Such multilocus SNP characteriza-
tion would provide useful information for understanding the
patterns, causes and control of P. jirovecii infection.
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